Compare CRCT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRCT | CGEM |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 857.6M | 794.7M |
| IPO Year | 2021 | 2020 |
| Metric | CRCT | CGEM |
|---|---|---|
| Price | $4.08 | $14.42 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $3.50 | ★ $30.11 |
| AVG Volume (30 Days) | 600.2K | ★ 749.6K |
| Earning Date | 03-03-2026 | 03-10-2026 |
| Dividend Yield | ★ 23.00% | N/A |
| EPS Growth | ★ 20.69 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $708,780,000.00 | N/A |
| Revenue This Year | $0.08 | N/A |
| Revenue Next Year | $0.98 | $79.85 |
| P/E Ratio | $11.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.92 | $5.68 |
| 52 Week High | $7.33 | $16.74 |
| Indicator | CRCT | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 55.91 |
| Support Level | $3.92 | $11.43 |
| Resistance Level | $4.57 | $16.74 |
| Average True Range (ATR) | 0.12 | 0.86 |
| MACD | 0.02 | -0.18 |
| Stochastic Oscillator | 47.83 | 50.75 |
Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.